[c09aa8]: / clusters / 9knumclustersv2 / clust_620.txt

Download this file

38 lines (37 with data), 3.5 kB

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
Ascites or pleural effusion requiring intervention or that required intervention or recurred within three months prior to randomization
Have symptomatic ascites or pleural effusion.
Symptomatic ascites or pleural effusion.
Evidence of fluid retention at Screening (including, for example, peripheral edema, pleural effusion, or ascites on physical or radiological examination) or history of severe capillary leak syndrome
Symptomatic ascites or pleural effusion
Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
Has ascites or pleural effusion by physical exam
Has symptomatic ascites or pleural effusion.
Clinical ascites or metastatic pleural fluid
Patients with pleural effusion or abdominal/peritoneal ascites, except the finding of physiological levels of fluid.
Symptomatic ascites or pleural effusion.
Marked pleural effusion or ascites above Grade , based on NCI-CTCAE v. criteria
Patients with symptomatic ascites or pleural effusion; a patient who is clinically stable following treatment for these conditions is eligible
Symptomatic ascites or pleural effusion
Subjects with significant fluid retention, including ascites or pleural effusion, may be allowed at the discretion of the Principal Investigator (PI)
Has symptomatic ascites or pleural effusion
Symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
Has ascites that requires frequent paracentesis or a pleural effusion that requires repeated thoracentesis
For Cohort B: Has ascites and/or clinically significant pleural effusion
Grade - ascites or pleural effusion\r\n* Note: The following will NOT be exclusionary: A participant who is clinically stable following treatment for ascites or pleural effusion (including therapeutic thoracentesis or paracentesis)
Has symptomatic ascites or pleural effusion.
Symptomatic ascites or pleural effusion
Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).
Symptomatic ascites or pleural effusion
Patients with symptomatic ascites or pleural effusion; a patient who is clinically stable following treatment for these conditions is eligible
No clinically significant evidence of pleural effusion or ascites
Patients with only non-measurable lesions other than bone metastases (e.g., pleural effusion, ascites, etc)
Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.
Has symptomatic ascites or pleural effusion
Subject's with significant fluid retention, including ascites or pleural effusion, may be allowed at the discretion of the principal investigator (PI)
Pleural effusion or ascites > liter
Clinically significant (in the opinion of the Investigator) ascites or pleural effusion requiring chronic medical intervention
Pleural effusion or clinically evident (visible or palpable) ascites
Pre-existing ascites (abdominal fluid collection) and/or clinically significant pleural effusion ( fluid collection between the lung and chest wall)
Uncontrolled pleural effusion or ascites
Signs of third spacing as determined by the treating physician (e.g., pedal edema, pleural effusion, ascites)
Has symptomatic ascites or pleural effusion